Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STIM
STRONG SELLNeuronetics, Inc. · Healthcare · United States · $120M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Neuronetics, Inc. is a medical device company that develops and markets the NeuroStar Advanced Therapy system, a non-invasive transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD). The company holds a leading position in the TMS market, benefiting from FDA clearance and clinical validation for its technology. Neuronetics provides an important drug-free alternative for patients who have not achieved satisfactory results with antidepressant medications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.2M | 71.3M | 74.9M | 149.2M | 31.8% | 151.6M | 161.1M | 177.2M | 9.0% |
| EPS | -0.54 | -0.44 | -1.37 | -0.59 | — | -0.67 | -0.47 | -0.34 | — |
| Shares | 69.6M | 69.6M | 55.7M | 69.0M | -0.9% | 69.6M | — | — | — |
| Debt | 39.7M | 62.5M | 82.6M | 90.3M | 31.5% | 85.4M | — | — | — |
| Equity | 57.1M | 34.2M | 27.7M | 22.4M | -26.8% | — | — | — | — |
| Op CF | -30.7M | -32.0M | -31.0M | -20.4M | — | -12.8M | — | — | — |
| Inv CF | 6.7M | -1.3M | -2.4M | -0.8M | — | — | — | — | — |
| Fin CF | 0.2M | 22.7M | -6.8M | 35.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STIM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STIM | Neuronetics, Inc.(you) | $120M | 15 | STRONG SELL |
| CVRX | CVRx, Inc. | $126M | 12 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 19 | STRONG SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
| OWLT | Owlet, Inc. | $153M | 11 | STRONG SELL |
| OM | Outset Medical, Inc. | $75M | 15 | STRONG SELL |
| QSI | Quantum-Si incorporated | $168M | 11 | STRONG SELL |
| QTRX | Quanterix Corporation | $173M | 20 | STRONG SELL |
| LUCD | Lucid Diagnostics Inc. | $173M | 9 | STRONG SELL |
| MXCT | MaxCyte, Inc. | $116M | 28 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%